San Diego Venture Group; Venture Summit 2013; Presnell
Upcoming SlideShare
Loading in...5
×
 

San Diego Venture Group; Venture Summit 2013; Presnell

on

  • 342 views

Organovo's Sharon Presnell, Ph.D., presents "Shaping the Future of Medicine…from better drugs to tissue on-demand"

Organovo's Sharon Presnell, Ph.D., presents "Shaping the Future of Medicine…from better drugs to tissue on-demand"

Statistics

Views

Total Views
342
Views on SlideShare
300
Embed Views
42

Actions

Likes
0
Downloads
5
Comments
0

2 Embeds 42

http://www.sdvg.org 41
http://www.newsblur.com 1

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    San Diego Venture Group; Venture Summit 2013; Presnell San Diego Venture Group; Venture Summit 2013; Presnell Presentation Transcript

    • Shaping  the  Future  of  Medicine…    from  be6er  drugs  to  8ssue  on-­‐demand   Sharon  Presnell,  Ph.D.   Chief  Technology  Officer       © Copyright 2013, Organovo Holdings, Inc. This report is solely for the use of intended audience. No part of it may be circulated, quoted, or reproduced for distribution outside the organization without prior written approval from Organovo Holdings, Inc.
    • SAFE HARBOR STATEMENT 2   NYSEMKT:  ONVO     ©Copyright  2013  Organovo,  Inc.   Any   statements   contained   in   this   presentaAon   that   do   not   describe   historical   facts   may   consAtute   forward-­‐looking   statements   as   that   term   is   defined   in   the   Private   SecuriAes   LiAgaAon  Reform  Act  of  1995.  Any  forward-­‐looking  statements  contained  herein  are  based  on   current  expectaAons,  but  are  subject  to  a  number  of  risks  and  uncertainAes.  The  factors  that   could  cause  actual  future  results  to  differ  materially  from  current  expectaAons  include,  but   are  not  limited  to,  risks  and  uncertainAes  relaAng  to  the  Company's  ability  to  develop,  market   and   sell   products   based   on   its   technology;   the   expected   benefits   and   efficacy   of   the   Company’s  products  and  technology;  the  availability  of  substanAal  addiAonal  funding  for  the   Company   to   conAnue   its   operaAons   and   to   conduct   research   and   development,   clinical   studies   and   future   product   commercializaAon;   and,   the   Company's   business,   research,   product  development,  regulatory  approval,  markeAng  and  distribuAon  plans  and  strategies.   These  and  other  factors  are  idenAfied  and  described  in  more  detail  in  our  filings  with  the  SEC,   including  our  annual  report  for  the  period  ended  December  31,  2012    on  Form  10-­‐K  and  our   current   reports   filed   on   Form   8K.   We   do   not   undertake   to   update   these   forward-­‐looking   statements  made  by  us.    
    • 3  
    • 4   KIDNEY  DONORS   Data  Sources:   •  USRDS   •  UNOS   KIDNEY  TRANSPLANT  WAITLIST  
    • 5   KIDNEY  DONORS   Data  Sources:   •  USRDS   •  UNOS   KIDNEY  TRANSPLANT  WAITLIST   PEOPLE  WITH  END-­‐STAGE  RENAL  FAILURE   PEOPLE  WITH  MID-­‐  TO  LATE-­‐STAGE  CKD  
    • Target  Discovery   Lead  ID   Lead   Op<miza<on   ADMET   Development   Registra<on   and  approval   6   Living human cells are widely used in drug development and regenerative medicine ©Copyright  2013  Organovo,  Inc.   CELL-­‐BASED  ASSAYS   CELLS  &  TISSUES  AS  THERAPEUTIC  AGENTS   From  Zreiqat  et  al.,  Biomaterials   2010  31:3175    
    • 7   (NYSEMKT:  ONVO)   •  Founded  in  2007,  based  on  proprietary  bio-­‐prinAng   technology  developed  at  the  University  of  Missouri   with  a  $5M  NaAonal  Science  FoundaAon  grant   •  Based  in  San  Diego  in  a  15,000  sq  i  facility  with   dedicated  bioprinAng    /  Assue  culture  and  analyAcal   laboratories     •  A  leader  in  “3D  prinAng”  of  human  Assue  targeAng  in   vitro  and  in  vivo  applicaAons   2012 ©Copyright  2013  Organovo,  Inc.  
    • 8  
    • Peripheral  Nerve   Lung   Bone   Blood  Vessel   Skeletal  Muscle   Liver   Cardiac   ©Copyright  2013  Organovo,  Inc.  
    • Organovo’s 3D Human Liver Tissue Array Standard  Corning  TranswellTM  Plates     •  Automated,  reproducible   •  Represents  naAve  human  Assue   10   ©Copyright  2013  Organovo,  Inc.   NATIVE  LIVER  TISSUE   ONVO  3D  LIVER  TISSUE   LIVER  CELLS  ON  3D  SCAFFOLD   From  Mat  Sci  Eng  2012  C32:310  
    • Organovo’s 3D Human Liver Tissue Array •  Automated,  reproducible   •  Represents  naAve  human  Assue   •  Exhibits  superior  funcAon   11   ©Copyright  2013  Organovo,  Inc.      ONVO                Standard   3D                              2D           LIVER-­‐SPECIFIC  PROTEIN  SECRETION   (ng  Albumin  /  mL  /  million  cells)    *    p  <  0.001  
    • Enabling blood supply… A critical step in building implantable tissues From  establishing  microvascular  networks…     …to  simple  blood  vessels     …to  branched  vascular  trees     Vascular  Networks  (brown)  in   bioprinted  human  Assue   Bioprinted   Branched  Vessel  
    • 13   ©Copyright  2013  Organovo,  Inc.   Partner Companies & Institutions